Evidence map›Paper›PMID 40437571›Full record

ArticleBMC medicine2025

A matters arising: discussion on urokinase dosing and individualized treatment strategies in the TRUST trial.

Yue Qiao, Xunming Ji, Wenbo Zhao

Abstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Yue QiaoDepartment of Neurology, Xuanwu Hospital, Capital Medical University, No. 45, Changchun Street, Xicheng District, Beijing, 100053, China.
Xunming JiDepartment of Neurology, Xuanwu Hospital, Capital Medical University, No. 45, Changchun Street, Xicheng District, Beijing, 100053, China.
Wenbo ZhaoDepartment of Neurology, Xuanwu Hospital, Capital Medical University, No. 45, Changchun Street, Xicheng District, Beijing, 100053, China. zhaowb@xwh.ccmu.edu.cn.

Funding

Beijing Natural Science Fund for Outstanding Young Scholars JQ22020National Natural Science Fund of China 82422024
6 · The paper itself

Abstract

This matters arising addresses the recently published article in BMC Medicine by Tao Y et al., entitled "Effect of intravenous urokinase vs best medicine treatment on functional outcome for patients with acute minor stroke (TRUST): a randomized controlled trial." While appreciating the rigorous methodology and important findings of the TRUST trial, we raise several points regarding optimizing urokinase dosing and treatment strategies. Specifically, we discuss the potential for optimizing urokinase dosing based on emerging evidence. Given China's extensive clinical experience with urokinase and associated cost considerations, we advocate for further research, including trials evaluating weight-based dosing strategies, to optimize urokinase thrombolytic therapy for patients with acute ischemic stroke. Such research is crucial for optimizing urokinase thrombolysis and establishing its role as a cost-effective treatment option, especially in resource-limited settings.

Indexed as

Fibrinolytic AgentsStrokeThrombolytic TherapyUrokinase-Type Plasminogen ActivatorHumansPrecision MedicineRandomized Controlled Trials as TopicFibrinolytic AgentsUrokinase-Type Plasminogen ActivatorAcute ischemic strokeIntravenous thrombolysisTRUST trialUrokinase

Identifiers

PMID40437571
PMCPMC12121243

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.